Editor: Luigia Scudeller

Introduction {#sec1}
============

Since its emergence in China \[[@bib1]\], SARS-CoV-2 has spread at an extraordinary pace. In Germany, the first case of SARS-CoV-2 infection was detected on January 27, 2020 \[[@bib2]\]. Germany rapidly implemented testing capacities for SARS-CoV-2, and the national Public Health institute (Robert Koch-Institute, RKI), provided recommendations for testing \[[@bib3]\]. Charité -- Universitätsmedizin Berlin opened the SARS-CoV-2 test site on Campus Virchow-Klinikum located in the north-west of Berlin one day after the first COVID-19 patient was identified in the city. The site aimed to provide testing for the general population, and to reduce workload for the emergency departments. Because clinical manifestations range from absent or unspecific signs to severe acute respiratory distress \[[@bib4]\], COVID-19 patients may visit different medical departments, and thus pose a risk of transmission among medical staff across the hospital \[[@bib5]\].

Most clinical descriptions have focused on COVID-19 among hospitalized patients, with fever, fatigue, dry cough, and shortness of breath as common symptoms \[[@bib6], [@bib7], [@bib8]\]. Patients with mild symptoms have not been investigated extensively, although this group may contribute to community transmission, thereby impeding containment efforts \[[@bib9], [@bib10]\].

The Charité test site offered the possibility to consult patients with suspicion of SARS-CoV-2 infection and to assess the proportion of infected individuals among outpatients during the early epidemic. The present analysis of \>5000 patients aims at describing the epidemiological characteristics and the clinical manifestation of SARS-CoV-2 infection to identify factors associated with SARS-CoV-2 detection in an outpatient setting.

Methods {#sec2}
=======

The first COVID-19 case in Berlin was identified on March 2, 2020. The test site commenced operations on March 3, 2020, with opening hours from 8:00 to 16:00 (20:00).

Upon presentation, physicians interviewed patients *via* an intercom with visual contact through window screens. Taking of medical history and assessment of symptoms were guided by a questionnaire also available as a web application "CovApp"(<https://covapp.charite.de/>). If indicated, a combined oro- and nasopharyngeal swab was obtained and tested for SARS-CoV-2 using reverse transcriptase polymerase chain reaction (RT-PCR) in the central hospital laboratory \[[@bib11]\]. Other respiratory pathogens were not tested, and patients were not examined physically.

The decision on testing largely followed RKI recommendations, which changed over time. Until March 23, 2020, they comprised mainly symptomatic individuals either with contact to SARS-CoV-2 cases, or with return from an area of risk, as determined and continuously redefined by the RKI, within 14 days before disease. As of March 24, only individuals with acute respiratory symptoms *with* contact to confirmed SARS-CoV-2 cases, or *without* contact depending on risk factors including occupation, age and underlying clinical conditions remained, please see the Appendix for details. If test capacity was sufficient, acute respiratory symptoms alone justified testing, and ultimately, testing was based on the attending physician´s discretion. Usage of the test site was also influenced by the implementation of video consultations and an ordinance on contact restrictions effective March 23, 2020, stating that persons "shall stay in their home at all times".

For the present analysis, ethical approval was obtained from Charité´s institutional review board (EA4/083/20). Data width and granularity differed partially between patients, because the designated risk areas were modified over time and impaired sense of smell/taste was added as symptom. Data were continuously entered into the hospital information system. After extraction, data were pseudonomyzed for analysis.

Descriptive analyses comprised clinical and epidemiological factors among patients with positive and negative test results (undetermined test results labeled as negative), and among patients with and without SARS-CoV-2 test. Wilcoxon-Rank sum test was used to compare continuous data, χ^2^ test was used for categorical data. The primary analysis examined potential risk factors for SARS-CoV2 infection. We calculated crude and adjusted odds ratios with 95% confidence intervals (Wald) with the outcome SARS-CoV2 infected patient using logistic regression models. Independent variables available that made clinical sense for this analysis were age, sex, underlying diseases, referral types, travel destinations, duration since return from travel (no travel/return ≤7 d/return 8-14 d/return \>14 d/return date missing), contact to known SARS-CoV-2 case, duration since last contact (no contact/contact ≤7 d/contact 8-14 d/contact \>14 d/contact date missing), symptom types and duration since onset of symptoms (no symptoms/symptoms ≤7 d/symptoms 8-14 d/symptoms \>14 d/symptom date missing). For parameters of duration, missing data were included as an own category. Sensitivity analyses among all patients tested included i) an analysis of factors potentially on the causal pathway of SARS-CoV2 (excluding symptoms and times), ii) separate models for the first and last four weeks with different screening recommendations and initiation of contact/travel restrictions, iii) and separate models with undetermined test results labeled positive. For all multivariable regression models, P-values were calculated using type III test, which examines the significance of each partial effect in consideration of interaction with other effects in the model. Variable selection was stepwise forward with P\<0.05 for entering factors into the model, P\<0.06 for removing factors, and P-values below 0.05 considered significant. No interactions were tested in the models. Age and sex were included into all models, and patients for whom the data were not collected were included as NA (not applicable) into the models. For each model c-statistic was calculated. Analyses were exploratory in nature. All analyses were performed using R (software), SPSS \[IBM SPSS statistics, Somer, NY, USA\] and SAS \[SAS Institute, Cary, NC, USA\].

Results {#sec3}
=======

Patient attendance, positivity rate, and associated factors {#sec3.1}
-----------------------------------------------------------

Between March 3 and April 13 2020, 5179 patients consulted the test site ([Figure 1](#fig1){ref-type="fig"} ).Figure 1Patient attendance and SARS-Cov-2 positivity.Figure 1

1a) Number of consultations, tests and positive cases by calendar week (which are shifted by one day and start on Tuesday). 1b) Number of patients tested and tested positive if decision on testing strictly followed RKI recommendations. 1c) Number of tested patients missed by RKI recommendations Of the patients attending, 83.7% (N=4333) were tested for the presence of SARS-CoV-2, with 333 positive and 38 undetermined test results (7.7% and 0.9%, respectively). None of the patients with an undetermined test result was tested again. [Table 1](#tbl1){ref-type="table"} shows the basic patient characteristics of patients tested, and [Table S5 (Appendix)](#appsec1){ref-type="sec"} shows a comparison of the patients tested and not tested for SARS-CoV-2. The proportion of patients tested among all patients consulted declined over the course of the six weeks.Table 1Basic characteristics of patients with SARS-COV-2 among all patients tested (N=4333)Table 1TotalNegativePositivePositive % among patients tested (Total)Crude OR (95%CI)P-Value[a](#tbl1fna){ref-type="table-fn"}Patients433340003337.69Age, Median (IQR)34 (26-47)34 (26-47)34 (28-47)1.00 (1-1.01)0.269Male sex, N (%)2127 (49.1%)1938 (48.5%)189 (56.8%)8.891.40 (1.12-1.75)0.004Chronic lung disease418 (9.6%)388 (9.7%)30 (9%)7.180.92 (0.62-1.36)0.682Chronic heart disease259 (6%)244 (6.1%)15 (4.5%)5.790.73 (0.43-1.24)0.241Diabetes108 (2.5%)101 (2.5%)7 (2.1%)6.480.83 (0.38-1.8)0.635Obesity135 (3.1%)126 (3.2%)9 (2.7%)6.670.85 (0.43-1.7)0.652Referral Charité employee433 (10%)414 (10.4%)19 (5.7%)4.390.52 (0.33-0.84)0.008 Without referral1843 (42.5%)1675 (41.9%)168 (50.5%)9.121.43 (1.14-1.79)0.002 Referral from doctor558 (12.9%)529 (13.2%)29 (8.7%)5.200.61 (0.41-0.9)0.013 Other[b](#tbl1fnb){ref-type="table-fn"}644 (14.9%)597 (14.9%)47 (14.1%)7.300.88 (0.65-1.18)0.387 No data855 (19.7%)785 (19.6%)70 (21%)8.191.09 (0.83-1.44)0.539Travel No travel3309 (76.4%)3066 (76.7%)243 (73%)7.340.82 (0.64-1.06)0.130 Austria119 (2.7%)96 (2.4%)23 (6.9%)19.333.02 (1.89-4.83)\<.0001 USA21 (0.5%)17 (0.4%)4 (1.2%)19.052.85 (0.96-8.52)0.061 Switzerland31 (0.7%)28 (0.7%)3 (0.9%)9.681.29 (0.39-4.27)0.677 Spain44 (1%)40 (1%)4 (1.2%)9.091.2 (0.43-3.39)0.725 France33 (0.8%)30 (0.8%)3 (0.9%)9.091.2 (0.37-3.96)0.761 Within Germany228 (5.3%)209 (5.2%)19 (5.7%)8.331.1 (0.68-1.78)0.706 Italy244 (5.6%)235 (5.9%)9 (2.7%)3.690.45 (0.23-0.87)0.019 Other[c](#tbl1fnc){ref-type="table-fn"}260 (6%)241 (6%)19 (5.7%)7.310.94 (0.58-1.53)0.814 Destination missing44 (1%)38 (1%)6 (1.8%)13.641.91 (0.8-4.56)0.143Time since return, Median days (IQR)7 (3-1)7 (3-14)9 (3-15)0.635 No travel3309 (76.4%)3066 (76.7%)243 (73%)7.341=reference0.245[d](#tbl1fnd){ref-type="table-fn"} ≤ 7 days403 (9.3%)367 (9.2%)36 (10.8%)8.931.24 (0.86-1.79)0.254 8-14 days264 (6.1%)245 (6.1%)19 (5.7%)7.200.98 (0.6-1.59)0.930 \> 14 days233 (5.4%)207 (5.2%)26 (7.8%)11.161.59 (1.03-2.43)0.035Return date missing124 (2.9%)115 (2.9%)9 (2.7%)7.260.99 (0.5-1.97)0.971ContactContact to confirmed COVID-19 case1645 (38%)1456 (36.4%)189 (56.8%)11.492.29 (1.83-2.88)\<.0001Time since last contact, Median days (IQR)6 (3-9)6 (3-9)6 (3-8)0.707 No contact2688 (62%)2544 (63.6%)144 (43.2%)5.361=reference\<.0001[d](#tbl1fnd){ref-type="table-fn"} ≤ 7 days815 (18.8%)723 (18.1%)92 (27.6%)11.292.25 (1.71-2.96)\<.0001 8-14 days503 (11.6%)433 (10.8%)70 (21%)13.922.86 (2.11-3.87)\<.0001 \> 14 days134 (3.1%)125 (3.1%)9 (2.7%)6.721.27 (0.63-2.55)0.499 Contact date missing193 (4.5%)175 (4.4%)18 (5.4%)9.331.82 (1.09-3.04)0.023SymptomsPresence of any symptoms3890 (89.8%)3569 (89.2%)321 (96.4%)8.253.23 (1.80-6.37)\<.0001Time since symptom onset, Median days (IQR)4 (2-7)4 (2-7)4 (2-7)0.440 No symptoms443 (10.2%)431 (10.8%)12 (3.6%)2.711=reference\<.0001[d](#tbl1fnd){ref-type="table-fn"} ≤ 7 days2060 (47.5%)1877 (46.9%)183 (55%)8.883.50 (1.94-6.34)\<.0001 8-14 days700 (16.2%)629 (15.7%)71 (21.3%)10.144.05 (2.17-7.57)\<.0001 \> 14 days330 (7.6%)316 (7.9%)14 (4.2%)4.241.59 (0.73-3.49)0.246 Symptom date missing800 (18.5%)747 (18.7%)53 (15.9%)6.632.55 (1.35-4.82)0.004Recommended for testing by RKI2530 (58.4%)2268 (56.7%)262 (78.7%)10.362.82 (2.15-3.69)\<.0001[^2][^3][^4][^5][^6]

As outlined above, RKI test recommendations broadened over time. As of March 24, suspected cases without epidemiological link were included. RKI recommendations were followed in 58.4% (N=2530/4333) of patients. In this subgroup, test positivity was more than twice as high compared to tests without recommendation (10.4%, 262/2530 vs. 3.9%, 71/1803, [Figure 1](#fig1){ref-type="fig"}). Among all patients tested positive, 21.3% were identified outside of RKI recommendations (71/333).

In addition, we analyzed several subgroups. On March 6, local health authorities informed the public of a COVID-19 case who had visited a nightclub on February 29. Between March 6 and March 16, 94 persons who had visited the club the same evening presented at the test site. Of those, 27.7% (26/94) tested positive, representing 74.2% (23/31) of all confirmed cases at the test site during the first week. RKI would not have recommended 23.4% (22/94) of club visitors for testing, of which 27.3% (6/22) had a positive test result.

Charité employees comprised 8.6% of the attendees (447/5179), and among those tested (433/4333), 4.4% (19/433) were positive. Of all Charité employees tested, 28.9% (125/433) did not report any symptom as opposed to 8.2% (318/3900) of other patients. RKI recommendations would have classified 45.5% of Charité employees for testing (197/433), and 26.3% (5/19) of those tested positive would have been missed. Previous contact with a confirmed case was reported by 56.3% (232/433) of Charité employees and 36.3% (1413/3900) of other patients; test results of Charité employees with contact were less often positive (2.4%, 8/232 *vs.* 12.8%, 181/1413).

Clinical presentation of SARS-CoV-2 infection {#sec3.2}
---------------------------------------------

The clinical picture of patients who tested positive was, though still mild, relatively more severe, with higher proportions of body aches, chills, fatigue, fever, headache and rhinorrhea ([Table 2](#tbl2){ref-type="table"} , [Figure 2](#fig2){ref-type="fig"} ). SARS-CoV-2 positive patients showed an increased proportion of affected sense of smell/taste compared to patients who tested negative, but 72.4% (21/29) also showed symptoms of rhinorrhea. Chemosensory dysfunction was the only symptom with some use to differentiate between SARS-CoV-2 infection and other respiratory illness with 85.6% specificity (95%CI, 82.1-88.1%); its sensitivity in detecting SARS-CoV-2 infection was 39.7% (95%CI, 28.5-51.0%); positive and negative predictive values were 20.6% (95%CI, 13.9-27.2) and 93.8% (95%CI, 91.0-95.6), respectively.Table 2Symptoms at presentation among patients tested positive or negative for SARS-CoV-2Table 2Negative, N=4000Positive, N=333P-ValueN%N%No symptoms43110.8123.6\<0.001Fever96824.212136.3\<0.001Shortness of breath59714.96118.30.098Chest tightness/pain3087.7267.80.943Chills82720.712236.6\<0.001Fatigue188847.221263.7\<0.001Body aches114528.617151.4\<0.001Cough240560.121865.50.056Rhinorrhea159439.916248.60.002Diarrhoea54713.75115.30.405Sore throat198449.615947.70.516Headache171342.818756.2\<0.001Impaired smell/taste, N=850112/77714.429/7339.7\<0.001Figure 2Symptoms of patients tested positive and negative for SARS-CoV2. Crude, unadjusted Odds ratios. \* represents findings for a subset of N=850 patients.Figure 2

[Table 3](#tbl3){ref-type="table"} presents the multivariate analysis of factors associated with the detection of SARS-CoV-2 infection.Table3Multivariate analysis of factors associated with of SARS-Cov2 infectionTable3Adjusted Odds Ratio95% Confidence IntervalAge (years)1.011(1.002-1.019)Male sex1.397(1.103-1.769)Chronic heart disease0.546(0.307-0.971)Without referral1.42(1.122-1.798)Contact to known SARS-CoV-2 case No contact1=reference ≤ 7 days3.177(2.361-4.274) 8-14 days3.415(2.475-4.711) \> 14 days1.283(0.619-2.663) Last date of contact missing2.527(1.462-4.367)Travel Travel to USA3.893(1.241-12.207) Travel to Austria4.163(2.48-6.989)Time since onset of symptoms. Reference no symptoms1=reference ≤ 7 days2.674(1.426-5.016) 8-14 days3.613(1.871-6.977) \> 14 days1.498(0.661-3.396) Date symptom onset missing2.355(1.208-4.592)Symptom type Fever1.412(1.081-1.843) Chills1.496(1.136-1.972) Body aches2.155(1.664-2.792) Sore throat0.613(0.479-0.783) Impaired sense of smell/taste^a^ No impaired senste of smell/taste1=reference No data1.028(0.723-1.462) Impaired senste of smell/taste4.076(2.365-7.025)[^7]

The probability to detect SARS-CoV-2 was influenced by patient factors, symptomatology, and travel to high prevalence countries, but also by time since disease onset or last contact to confirmed cases.

Sensitivity analyses for the first four and last four weeks confirmed the main findings from primary analysis ([Appendix TableS1](#appsec1){ref-type="sec"}). Separate models for factors supposedly on the causal pathway, for the entire 6 weeks and also broken down to the first and last four weeks identified the same risk factors, except for a protective effect for Charité employees ([Appendix TableS2](#appsec1){ref-type="sec"}). Risk factors associated with exposure were more pronounced in the first four weeks, before the test recommendations changed and contact restrictions were imposed ([Appendix TableS1 and TableS2](#appsec1){ref-type="sec"}). Sensitivity analysis with undetermined laboratory results labeled positive instead of negative confirmed all previous findings ([Appendix S3-S4](#appsec1){ref-type="sec"}).

Discussion {#sec4}
==========

In this description of SARS-CoV-2 infected individuals from the early epidemic in Berlin, Germany, most patients were young and showed mild symptoms of a respiratory tract infection. Important risk factors for detection of SARS-CoV-2 infection were recent contact to a positive case, travel to designated areas of risk, recent onset of symptoms, symptoms including impaired sense of smell/taste and unspecific symptoms such as fever, chills and body aches.

As of April 14, Berlin counted 4,668 cases \[[@bib12]\], 333 of which had been identified at the Charité test site (7%). If we had tested patients strictly according to RKI recommendations, more than 20% of SARS-CoV-2 infected individuals attending the site would have been missed and could have contributed to additional silent community transmission. This illustrates the delicate balance between efficient use of limited resources *vs.* broadening test indications to identify otherwise undetected carriers.

Travelling abroad was a risk factor for SARS-CoV2 infection, particularly in the weeks following winter holidays in February. Among risk areas as determined by RKI, returnees from Austria, a popular destination for winter sports, had a four times increased chance to have a positive test result. Anecdotally, a single bar in an Austrian ski resort was a transmission hotspot, which only became apparent with increasing numbers of sick returnees \[[@bib13], [@bib14]\]. In contrast, extensive media coverage on the COVID-19 tragedy in Italy might have alerted the public and caused returnees from non-affected Italian regions to attend the test site. This could explain why returnees from a country with a high case number had reduced odds of infection.

Unsurprisingly, exposure to COVID-19 cases was associated with SARS-CoV2 infection. However, a considerable number of exposed patients tested negative, including household members. As contact persons are usually tested once and tests could be realized either too early or too late to detect viral RNA, negative test results should be interpreted carefully. Secondary-attack rates for household members have been estimated around 16% \[[@bib15]\]. The extent of individual variation in the number of secondary cases (dispersion) may be substantial, but is yet undetermined \[[@bib16]\]. The transmission events within one crowded nightclub support temporary lock-down strategies and stress the importance of rapid contact tracing in potential superspreading events and isolation of cases without waiting for screening results to contain the outbreak.

The clinical suspicion of SARS-CoV-2 infection based on symptoms proved virtually impossible, as the pandemic reached Berlin during the peak of influenza and cold season \[[@bib17]\]. Almost two thirds of patients presented with cough, but respiratory symptoms did not predict positive test results. Only an impaired sense of smell/taste was clearly increased among SARS-CoV-2 infected patients, confirming olfactory disorders as potential early symptom of COVID-19 patients \[[@bib18], [@bib19]\]. We may have found symptoms more specific of SARS-CoV-2 if we had compared to other diseases, which was beyond the scope of the test site.

In our patients, the proportion of asymptomatic cases was relatively small, contrasting higher numbers reported elsewhere \[[@bib20]\]. One obvious explanation is the largely symptom-based screening. However, more than one in four among hospital staff was asymptomatic upon presentation, indicating the risk of undetected nosocomial transmission.

Symptom/risk-based screening screening is widely used to contain the epidemic \[23\] and may yield more diagnoses compared to a less restricted strategy, but detection of SARS-CoV-2 clearly depended on the time since the symptoms began. Some patients may have been tested beyond the detection period, as viral RNA concentrations appear to decline rapidly after infection, and could fall below detection thresholds after day 5 of disease onset \[[@bib21]\]. Considering the threat posed by silent transmission through asymptomatic carriage, less restricted screening approaches may be crucial to interrupt transmission chains with potentially dramatic consequences if health care staff or potential superspreaders are affected. Because screening without repeated sampling in persons tested negative may lead to a false sense of security, especially in settings with a high pre-test probability, targeted screening programs at potential transmission hubs such as personnel in long term care facilities or schools should encompass repeated sampling. Sentinel surveillance based on symptoms and/or absence from work, school or kindergartens could complement laboratory-based test strategies, speed-up detection of clusters, and trigger public health action, e.g. partial school closures, contact tracing and targeted testing.

There are limitations to our findings' validity and representativeness. The patient population may have changed over time, as did testing recommendations. Initial media reports on long waiting times and contact restrictions might have prevented patients from consulting the test site. Some patients could have exaggerated sympoms to obtain a test, while others may have been denied testing before they developed symptoms.

Conclusions {#sec5}
===========

These data from the first operational SARS-CoV-2 test site in Berlin illustrate the predominantly mild disease resembling common cold or influenza among outpatients. Impaired sense of smell/taste may have value as a clinical symptom to guide decision on whether or not to test patients, but warrants further evaluation. The absence of severe cases might result from the outpatient setting, the early phase of the epidemic, access to testing, and the young patient population.

Typical risk factors such as travel to high incidence regions, contact to positive individuals, and gatherings were identified for the majority of the patients, whereas the source of infection remained unsolved for others. The impact of a single spreading event (nightclub) on the early case count in Berlin cautions against using premature data for extrapolating figures. In light of potential transmission from mildly symptomatic and asymptomatic infected persons, potential superspreading events should entail rapid contact tracing and subsequent isolation regardless of testing, which may be a slow and insecure tool if the chance for contacts to be infected is high.

All screening strategies depend on public acceptance, access to and usage of testing capacities, and testing recommendations, among other factors. Broad-scale testing targeted at high risk populations such as travel returnees from high incidence regions and contacts to confirmed cases should be scheduled ideally within the first two weeks after contact and/or onset of symptoms.

Conflict of interest {#sec6}
====================

None declared.

Funding statement {#sec7}
=================

No specific funding was received for this work.

Contributions {#sec8}
=============

F.Maechler - prepared manuscript, collated and analysed data. M.Gertler contributed to manuscript, implemented and coordinated testing and data collection, Julia Hermes edited manuscript, coordinated data collection, W.v.Loon collated and analysed data, and prepared the figures; F.Schwab analysed data; B.Piening analysed data, edited manuscricpt, oversaw testing, S.Rojansky and M. Behnke extracted data; F.Hommes and A.K.Lindner collected data and edited manuscript; F.Kausch collected and collated data, and edited manuscript; S.Burock collected and analysed data; H.Roessig coordinated testing site; C.Hartmann, V.Kirchberger and A.Thieme coordinated digital data collection (covapp.de); P.Gastmeier oversaw testing and edited manuscript; F.Mockenhaupt oversaw testing, data collection and analysis, edited manuscript. J.Seybold directed roll-out, edited manuscript.

Appendix A. Supplementary data {#appsec1}
==============================

The following is the Supplementary data to this article:

We thank all medical and non-medical Charité staff who contributed to the rapid and effective implementation of patient management, testing and data-collection at SARS-CoV-2-testing site Charité -- Universitätsmedizin Berlin, Campus Virchow-Klinikum.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.cmi.2020.08.017>.

[^1]: These authors contributed equally to this article and share first authorship.

[^2]: Data are n (column %) unless indicated otherwise.

[^3]: χ^2^ test.

[^4]: Other referrals included referral via hotline, from local public health authorities or from employer.

[^5]: Other countries included China, Iran, and other countries with N\<10 travelers.

[^6]: Wilcoxon-Rank sum test.

[^7]: Parameters included into the model were age, sex, underlying diseases, referral types, duration since return from travel, travel destinations, duration since last contact, duration since onset of symptoms, and symptom types, a) data collected in a subset of patients (N=850); c-statistic (area unter the curve) = 0.741.
